secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jasper Therapeutics, Inc. (JSPR)
CIK:        0001788028
Form:       8-K
Filed at:   2024-10-15T23:59:59+00:00
Accession:  0001213900-24-087394
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jasper reports 93% clinical response rate in SPOTLIGHT study of briquilimab in CIndU
--------------------------------------------------------------------------------

- 14 of 15 patients (93%) achieved clinical response; 10 of 12 (83%) in 120mg cohort had complete response.
- No serious adverse events or grade 3+ adverse events reported; well-tolerated with no hair/skin changes.
- Initial BEACON study data in CSU expected week of January 6, 2025, including 180mg Q8W cohort.
- Regulatory clearance obtained to enroll 180mg dose cohort (n=12) in SPOTLIGHT; full results H1 2025.
- Significant tryptase reduction observed (66% at 2 weeks) correlating with clinical responses.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1788028/000121390024087394/0001213900-24-087394-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1788028/000121390024087394/ea0217519-8k_jasper.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-087394

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer